Actinium Pharmaceuticals’ mission is to develop and commercialize targeted radiotherapy treatments

Actinium Pharmaceuticals’ mission is to develop and commercialize targeted radiotherapy treatments that improve outcomes for cancer patients. Their vision is to become a leader in the field of radiopharmaceuticals, providing therapies that are both effective and well tolerated, ultimately enhancing the quality of life for patients. Actinium is primarily focused on developing treatments for hematologic (blood) cancers such as acute myeloid leukemia (AML) and multiple my eloma. These cancers often have limited treatment options and high relapse rates, highlighting the need for innovative therapies.While their main focus is on blood cancers, Actinium is also exploring the potential of their targeted radiotherapy platform for treating solid tumors. This expansion represents a significant opportunity to apply their technology to a broader range of cancers.